SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: NotAsBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 5/23/2017 6:28:39 PM - Followers: 715 - Board type: Free - Posts Today: 156

Cellceutix Corporation (CTIX)

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564

About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly-traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Cellceutix's psoriasis drug candidate Prurisol completed a Phase 2 trial and Cellceutix recently launched a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at


Ongoing Human Trials:
Product Pipeline:







Recent News and Press Releases:

SEC Filings (CIK:0001355250):

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f

Share Structure:  See SEC filing link above for current share structure


Cellceutix IP - Patent Filings:


Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
External Links: USPTO, USPTO Assignment, Espacenet

Investor Relations:

Following is a WEEKLY chart:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTIX News: Quarterly Report (10-q) 05/09/2017 04:09:09 PM
CTIX News: Amended Statement of Ownership (sc 13g/a) 04/28/2017 12:50:45 PM
CTIX News: Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance 04/17/2017 07:03:27 AM
CTIX News: Current Report Filing (8-k) 03/31/2017 04:25:24 PM
CTIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 03/29/2017 04:13:08 PM
#182860  Sticky Note B-UP Due Diligence (Rev. 5/22) sox040713 05/22/17 03:11:36 PM
#182459  Sticky Note Good NEWS...Cellceutix Completes Patient Enrollment of Final Cohort TheDane 05/18/17 09:40:08 AM
#180448  Sticky Note PART II *** Please Read DaubersUP 04/28/17 12:59:51 PM
#175709  Sticky Note CTIX Milestones, Clinical Trials, Recent Interviews, Fact Sheets sox040713 03/18/17 06:44:12 PM
#174938  Sticky Note B-UP Due Diligence (Rev. 3/10) sox040713 03/10/17 04:08:53 PM
#183073   That was also when everyone assumed absssi would scottsmith 05/23/17 06:36:57 PM
#183072   That's around 6 bucks. Oughta be there soon. TheDane 05/23/17 06:31:45 PM
#183071   Second that opinion for the most part untohim 05/23/17 06:30:37 PM
#183070   Yahoo! Maybe we'll overcorrect to compensate for the TheDane 05/23/17 06:30:02 PM
#183069   NPV $3.50. Have seen only fully developed analysis untohim 05/23/17 06:28:39 PM
#183068   We were at around $3.50 when the shorting TheDane 05/23/17 06:28:05 PM
#183067   Meant to say only one. DesireToLearn 05/23/17 06:24:21 PM
#183066   NPV $3.50. Have seen only fully developed analysis DesireToLearn 05/23/17 06:19:30 PM
#183065   Very reasonable imo. scottsmith 05/23/17 06:11:28 PM
#183064   I still value this company in its current ROMAD Diver 05/23/17 06:09:35 PM
#183063   Interesting perspective. Great volume. What interests DaubersUP 05/23/17 06:08:45 PM
#183062   I disagree with the "new eyes" Mack. With alwaysdreaming 05/23/17 06:06:42 PM
#183061   Makes ya wonder. untohim 05/23/17 05:59:47 PM
#183060   good for them indeed! cybermich 05/23/17 05:57:03 PM
#183059   New Eyeballs -- You can be sure that MackG 05/23/17 05:34:56 PM
#183057   We are just getting started! Great day---> Matagordaville 05/23/17 05:32:43 PM
#183056   nice close Mata! my ctix account is now TheHound 05/23/17 05:31:00 PM
#183055   Don't forget about split potential!!!!! untohim 05/23/17 05:10:42 PM
#183054   If it wasn't ma and pa retail selling....then scottsmith 05/23/17 05:10:30 PM
#183053   Sold American!!!! untohim 05/23/17 05:10:00 PM
#183052   Hmmm, I guess retail isn't dead after all untohim 05/23/17 05:01:11 PM
#183051   Great opportunity here to lower cost basis! untohim 05/23/17 04:55:49 PM
#183050   backing off of a buck. its overbought and untohim 05/23/17 04:53:19 PM
#183049   Yep, I was happy with my .77s...but really Commando911 05/23/17 04:53:08 PM
#183048   You called it perfectly. ;) KarinCA 05/23/17 04:52:18 PM
#183047   perhaps its the 3 investors who are buying untohim 05/23/17 04:51:23 PM
#183046   Glad I added a few times when Fletch 05/23/17 04:40:39 PM
#183045   II's can drive it over $2 in the BioTechMaven 05/23/17 04:39:24 PM
#183044   3 month chart is hilarious. We need scottsmith 05/23/17 04:38:40 PM
#183043   $1.50 -----> $2.00----->$2.50 Sounds a Matagordaville 05/23/17 04:34:13 PM
#183042   Serious volume and momentum. Pulling in buyers. Nice farrell90 05/23/17 04:32:19 PM
#183041   CTIX could be the next 100 bagger. scottsmith 05/23/17 04:14:55 PM
#183040   As the Bio T Maven mentioned a market Matagordaville 05/23/17 04:12:12 PM
#183039   Good call Vlady. What do you call for tomorrow. L vus 05/23/17 04:10:31 PM
#183038   Maybe Maybe a short squeeze coming? JUST 10-11-12 05/23/17 04:09:50 PM
#183037   Looks like your "fluffing" worked. Above $1 near close. dougwur 05/23/17 04:02:53 PM
#183036   I think my $1.03 projections this morning were Vlady 1 05/23/17 04:00:46 PM
#183035   Nice Wild One...hard to believe we are excited Golfguru03 05/23/17 03:58:05 PM
#183034  Restored Yeah, that is some sled. septmike09 05/23/17 03:38:43 PM
#183033   Too many huge approaching milestones and undervalued for BioTechMaven 05/23/17 03:38:03 PM
#183032   Volume 568,000 and climbing Matagordaville 05/23/17 03:31:17 PM
#183031   Two bucks on deck. Volume hid her JUST 10-11-12 05/23/17 03:14:35 PM
#183030   Few flippers ... swapping for $0.05 profit .... Vlady 1 05/23/17 03:09:58 PM
#183029   Aruda must be buying... GregChase 05/23/17 03:02:18 PM
#183028   We knocked the .95 wall down tombrady12nh 05/23/17 02:58:54 PM
#183027   oh boy - here comes the profit taking. MXAMDUD 05/23/17 02:55:53 PM
#183026   Wild, I think you just won the internet Detonate 05/23/17 02:54:52 PM
#183025   YEP ! wild4ctix 05/23/17 02:52:54 PM
#183024   Patience is being rewarded to us longs! NanoEngineer 05/23/17 02:45:11 PM
#183023   Not for commercial use... Entertainment purposes only... Laugh, and enjoy Ringrock 05/23/17 02:44:03 PM